BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

PHI CSO Kersti Alm at Biostock

November 23, 2022

BioStock: PHI on the alliance for cell-based biomanufacturing

Kersti Alm, CSO at PHI, visited BioStock’s studio to talk about the recently created alliance for advancing cell-based biomanufacturing and PHI’s pivotal role in the collaboration.

PHI part of new regenerative medicine alliance

November 16, 2022

BioStock: PHI part of new regenerative medicine alliance

BioStock contacted Product Manager Lisa Lindström to learn more about PHI’s newly formed technology development alliance for regenerative medicine and what excites her about the future.

Biostock-regenerative-medicine-phi

October 21, 2022

BioStock: PHI expands market potential with regenerative medicine opportunity

BioStock contacted CFO Patrik Eschricht to find out more about PHI’s visions regarding regenerative medicine, cell-based therapies and automatization of biomanufacturing.

fill or kill podcast

PHI som gäst i Fill or Kill podcast: Avsnitt 366

Lyssna på Fill or Kill intervjun med PHI vd Peter Egelberg.

1…4 567 8